Revenue (Details)		1 Months Ended						3 Months Ended		6 Months Ended		85 Months Ended
	Apr. 19, 2022 USD ($) item	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2023 USD ($) customer	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) customer	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) customer	Dec. 31, 2022 USD ($)	Sep. 13, 2022 USD ($)
Grant Revenue
Revenue								$ 657,778	$ 50,981	$ 1,423,678	$ 263,399
Grant receivable													$ 1,524,522
Process Development Revenue
Process development revenue recognized								$ 700,000		$ 1,300,000
Number of customers process development revenue was derived from | customer								3		3		3
Process development contract liabilities, beginning of period										$ (1,618,308)
Reclassification to revenue as the result of performance obligations satisfied										1,323,678
Net change to contract balance recognized since beginning of period due to amounts collected										(2,439,894)
Process development contract liabilities, end of period								$ (2,734,524)		(2,734,524)		$ (2,734,524)
Shattuck
License Revenue
License fee received							$ 50,000
Proceeds from milestone payment			$ 100,000
ANTHIM Vials
Grant Revenue
Number of vials to be delivered | item	3,000
Contract award	$ 6,000,000.0
ANTHIM Vials | Accounts receivable
Grant Revenue
Contract with customer, receivable, after allowance for credit loss, current														$ 6,000,000.0
Product
Grant Revenue
Revenue								0	0	0	0
Pelican Therapeutics, Inc. | Grant and contract revenue
Grant Revenue
Revenue		$ 1,500,000						0	$ 0.0	0	$ 200,000	15,200,000
Remaining grant amount receivable		$ 1,500,000
Amount the company is required to match of each dollar of grant								0.50		0.50		0.50
Threshold amount for match of grant								1.00		1.00		1.00
Contribution to be made by Pelican								$ 7,600,000		$ 7,600,000		$ 7,600,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Maximum
Grant Revenue
Amount awarded from CPRIT grant							$ 15,200,000
Royalty percentage after threshold is met										1.00%
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 1
Grant Revenue
Revenue						$ 1,800,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 2
Grant Revenue
Revenue					$ 6,500,000
Pelican Therapeutics, Inc. | Grant and contract revenue | Tranche 3
Grant Revenue
Revenue				$ 5,400,000